natgillin/translations-raw huggingface dataset:
The full EPAR and risk management plan summary for Exviera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Exviera sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other information about Exviera
Druge informacije o zdravilu Exviera
The Agency therefore concluded that the benefits of Exviera outweigh its risks and recommended that it be approved for use in the EU.
Agencija je tako zaključila, da so koristi zdravila Exviera večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
This stops the hepatitis C virus from multiplying and infecting new cells.
S tem prepreči, da bi se virus hepatitisa C razmnoževal in okužil nove celice.
Almost all the patients in the studies had the virus cleared from their blood after 12 or 24 weeks.
Pri skoraj vseh bolnikih v študijah je bil po 12 ali 24 tednih virus odstranjen iz krvi.
The clearance rate was particularly high in patients infected with genotype 1b.
Odstranjevanje je bilo še zlasti uspešno pri bolnikih, okuženih z genotipom 1b.
What are the risks associated with Exviera?
Kakšna tveganja so povezana z zdravilom Exviera?
What benefits of Exviera have been shown in studies?
Kakšne koristi je zdravilo Exviera izkazalo v študijah?
What is Exviera and what is it used for?
Kaj je zdravilo Exviera in za kaj se uporablja?
Why is Exviera approved?
Zakaj je bilo zdravilo Exviera odobreno?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Exviera have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Exviera upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
For more information about treatment with Exviera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Exviera preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The combination of medicines used and the duration of treatment will depend on which genotype of hepatitis C virus the patient is infected with, the nature of the liver problems they have (for example, if they have liver cirrhosis (scarring) or their liver is not working properly) and whether they have received previous treatment.
Uporabljena kombinacija zdravil in trajanje zdravljenja sta odvisna od genotipa virusa hepatitisa C, s katerim je bolnik okužen, in vrste njegovih težav z jetri (ali gre na primer za cirozo (brazgotinjenje) jeter ali njihovo nepravilno delovanje), oziroma od tega, ali se je predhodno že zdravil.
It is not intended to provide practical advice on how to use Exviera.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Several varieties (genotypes) of hepatitis C virus exist and Exviera is recommended for use in patients with virus of genotypes 1a and 1b.
Obstaja več vrst (genotipov) virusa hepatitisa C, zdravilo Exviera pa je priporočeno za bolnike z virusom genotipa 1a in 1b.
It contains the active substance dasabuvir.
Zdravilo vsebuje zdravilno učinkovino dasabuvir.
Exviera is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus.
Zdravilo Exviera je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljenje odraslih s kroničnim (dolgotrajnim) hepatitisom C, tj. nalezljivo boleznijo jeter, ki jo povzroča virus hepatitisa C.
The most common side effects with Exviera when used with Viekirax and ribavirin (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), nausea, pruritus (itching), asthenia (weakness) and fatigue (tiredness).
Najpogostejši neželeni učinki zdravila Exviera, kadar se uporablja skupaj z zdravilom Viekirax in ribavirinom (ki lahko prizadenejo več kot 1 osebo od 10), so insomnija (nespečnost), navzeja (slabost), pruritus (srbenje), astenija (šibkost) in utrujenost.
In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Exviera in combination with Viekirax was effective in clearing the virus from the blood.
V šestih začetnih glavnih študijah, v katere je bilo vključenih približno 2 300 bolnikov, okuženih z genotipoma 1a ali 1b virusa hepatitisa C, je bilo zdravilo Exviera v kombinaciji z zdravilom Viekirax učinkovito pri odstranjevanju virusa iz krvi.
The active substance in Exviera, dasabuvir, works by blocking the action of an enzyme in the hepatitis C virus called ‘NS5B RNA-dependent polymerase', which the virus needs to multiply.
Zdravilna učinkovina zdravila Exviera, dasabuvir, deluje tako, da zavira delovanje encima v virusu hepatitisa C, imenovanega „polimeraza NS5B, odvisna od RNK“, ki ga virus potrebuje za svoje razmnoževanje.
For practical information about using Exviera, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Exviera naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Exviera can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in managing patients with chronic hepatitis C.
Predpisovanje in izdaja zdravila Exviera je le na recept, zdravljenje pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s kroničnim hepatitisom C.
Regarding its safety, although there were some cases of raised liver enzymes in patients treated with Exviera in combination with Viekirax and ribavirin, side effects seen with this combination were generally well tolerated.
Kar zadeva varnost, so bolniki kljub zabeleženim nekaj primerom povišanih jetrnih encimov pri bolnikih, zdravljenih z zdravilom Exviera v kombinaciji z zdravilom Viekirax in ribavirinom, neželene učinke pri tej kombinaciji na splošno dobro prenašali.
Exviera must not be used in women taking ethinylestradiol, an oestrogen found in hormonal contraceptives.
Zdravilo Exviera se ne sme predpisovati ženskam, ki jemljejo etinilestradiol, tj. vrsto estrogena, ki ga vsebujejo hormonska kontracepcijska sredstva.
Exviera is always used in combination with another medicine, Viekirax, which contains the active substances ombitasvir, paritaprevir and ritonavir.
Zdravilo Exviera se vedno uporablja v kombinaciji z zdravilom Viekirax, ki vsebuje zdravilne učinkovine ombitasvir, paritaprevir in ritonavir.
The European Medicines Agency noted that Exviera used in combination with Viekirax is effective in clearing the hepatitis C virus genotypes 1a and 1b from the blood with and without ribavirin.
Evropska agencija za zdravila je ugotovila, da zdravilo Exviera v kombinaciji z zdravilom Viekirax učinkovito odstranjuje virus hepatitisa C genotipov 1a in 1b iz krvi, in sicer v kombinaciji z ribavirinom in brez njega.
In a seventh study, patients with liver scarring but stable liver function (compensated cirrhosis) who had genotype 1b infection were treated with Exviera and Viekirax without ribavirin and 100% of patients (60 out of 60 patients) had their blood cleared of the virus.
V sedmi študiji so bolnike s cirozo jeter in stabilnim delovanjem jeter (kompenzirano cirozo), okužene z genotipom 1b, zdravili z zdraviloma Exviera in Viekirax brez ribavirina in pri 100 % (60 od 60) bolnikov je bil virus odstranjen iz krvi.
In patients with liver scarring, Exviera treatment in combination with Viekirax and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment.
Pri bolnikih s cirozo jeter, ki so prejemali zdravilo Exviera v kombinaciji z zdravilom Viekirax in ribavirinom, je bil po 24 tednih zdravljenja virus odstranjen pri 93-100 % bolnikov.
Some patients taking Exviera are also treated with another antiviral medicine, ribavirin, in addition to Viekirax.
Nekateri bolniki, ki jemljejo zdravilo Exviera, poleg zdravila Viekirax prejemajo tudi ribavirin, še eno protivirusno zdravilo.
Between 96% and 100% of patients without liver scarring had their blood cleared of the virus after 12 weeks of treatment (with or without ribavirin).
Pri 96-100 % bolnikov brez ciroze jeter po 12 tednih zdravljenja (brez ribavirina ali v kombinaciji z njim) ni bilo zaznati virusa v krvi.
The company that markets Exviera will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as
Družba, ki trži zdravilo Exviera, bo za oceno tveganja ponovitve raka jeter po zdravljenju z neposredno delujočimi protivirusnimi zdravili, kot je zdravilo Exviera, izvedla študijo pri bolnikih, ki so preboleli raka jeter.
How is Exviera used?
Kako se zdravilo Exviera uporablja?
How does Exviera work?
Kako zdravilo Exviera deluje?
It is generally given once a day, except in life-threatening situations.
Načeloma se daje enkrat dnevno, razen v življenjsko nevarnih situacijah.
Nonafact can be used in adults and children over the age of 6.
Nonafact se lahko uporablja pri odraslih in otrocih, starih več kot 6 let.
Patients may sometimes be able to give the medicine themselves after suitable training.
Bolniki si lahko dajo zdravilo sami, potem ko so bili za to ustrezno usposobljeni.
The full EPAR for Nonafact can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nonafact je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union, for Nonafact on 3 July 2001.
Evropska komisija je dovoljenje za promet z zdravilom Nonafact, veljavno po vsej Evropski uniji, izdala 3. julija 2001.
This is a summary of the European public assessment report (EPAR) for Nonafact.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Nonafact.
Most patients had severe haemophilia B. The studies assessed the number of major or life-threatening bleeding episodes that occurred during treatment, or during and after surgery.
Večina bolnikov je imela hudo hemofilijo B. V študijah so ocenjevali število večjih ali življenjsko nevarnih epizod krvavitev, do katerih je prišlo med zdravljenjem ali med kirurškim posegom in po njem.
If this happens Nonafact may not work effectively.
Če do tega pride, zdravilo Nonafact morda ne bo več učinkovito delovalo.
What measures are being taken to ensure the safe and effective use of Nonafact?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Nonafact?
Treatment should be started under the supervision of a doctor with experience in treating haemophilia.
Zdravljenje se lahko uvede le pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hemofilije.
Nonafact is intended for either short-term or long-term use.
Namenjen je za kratkotrajno ali dolgotrajno uporabo.
Nonafact human coagulation factor IX
Nonafact humani koagulacijski faktor IX
For more information about treatment with Nonafact, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Nonafact preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nonafact.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In the body, factor IX is one of the substances (factors) needed for blood coagulation (clotting).
Faktor IX je ena izmed snovi (faktorjev) v telesu, potrebnih za koagulacijo (strjevanje) krvi.
Nonafact has been studied in two clinical studies, including 26 patients who received Nonafact as a prevention treatment (for example before extensive exercise), and 8 patients who received Nonafact during 11 surgical interventions.
Zdravilo Nonafact so proučevali v dveh kliničnih študijah, ki sta zajeli 26 bolnikov, ki so prejemali Nonafact kot preventivno terapijo (npr. pred obsežno telesno vadbo), in nadaljnjih 8 bolnikov, ki so zdravilo Nonafact prejeli med 11 kirurškimi posegi.
The full detail on how to calculate the doses is included in the package leaflet.
Podrobni podatki o tem, kako izračunati ustrezni odmerek, so na voljo v navodilu za uporabo.
A risk management plan has been developed to ensure that Nonafact is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Nonafact je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Nonafact, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The dose is also adjusted depending on the severity of the haemorrhage or the type of surgery.
Odmerek je treba prilagoditi tudi glede na stopnjo resnosti krvavitve ali vrsto kirurškega posega.
Other information about Nonafact
Druge informacije o zdravilu Nonafact
Patients with haemophilia B lack factor IX, and this causes bleeding problems, such as bleeding in the joints, muscle or internal organs.
Bolnikom s hemofilijo B primanjkuje faktorja IX, kar povzroča težave s krvavitvami, kot so krvavenje v sklepe, mišice ali notranje organe.
Nonafact is given by infusion into a vein at a rate of no more than 2 ml per minute.
Zdravilo Nonafact se daje z infuzijo v veno s hitrostjo največ 2 ml na minuto.
For the full list of all the side effects reported with Nonafact, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Nonafact, glejte navodilo za uporabo.
What benefit has Nonafact shown during the studies?
Kakšne koristi je zdravilo Nonafact izkazalo med študijami?
The doctor will calculate a suitable dose, depending on whether Nonafact is used to treat haemorrhage (bleeding) or to prevent bleeding during surgery.
Zdravnik bo izračunal primeren odmerek glede na to, ali se zdravilo Nonafact uporablja za zdravljenje krvavitev ali za preprečevanje krvavitev med kirurškim posegom.
Nonafact must not be used in people who are hypersensitive (allergic) to human coagulation factor IX or to any of the other ingredients, or to mouse proteins.
Zdravila Nonafact ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) humani koagulacijski faktor IX ali katero koli drugo sestavino ali na mišje beljakovine.
Nonafact is used for the treatment and prevention of bleeding in patients with haemophilia B (an inherited bleeding disorder caused by lack of factor IX).
Zdravilo Nonafact se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo B (prirojeno motnjo strjevanja krvi zaradi pomanjkanja faktorja IX).
What is the risk associated with Nonafact?
Kakšna tveganja so povezana z zdravilom Nonafact?
The CHMP decided that Nonafact's benefits are greater than its risks for the treatment and prevention of bleeding in patients with haemophilia B. They recommended that Nonafact be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Nonafact za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo B večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Nonafact contains the active substance human coagulation factor IX, which helps blood to clot.
Nonafact vsebuje zdravilno učinkovino humani koagulacijski faktor IX, ki pomaga pri strjevanju krvi.
Nonafact is used to replace the missing factor IX; it corrects the factor IX deficiency and gives temporary control of the bleeding disorder.
Z zdravilom Nonafact se nadomesti manjkajoči faktor IX in posledično popravi njegovo pomanjkanje ter vzpostavi začasni nadzor nad krvavitvami.
Nonafact is a powder and solvent that are mixed together to form a solution for infusion (drip) into a vein.
Zdravilo Nonafact sestavljata prašek in vehikel, ki se zmešata v raztopino za infundiranje (kapalno infuzijo v veno).
Nonafact contains human coagulation factor IX, a protein extracted and purified from human plasma (the liquid part of the blood).
Zdravilo Nonafact vsebuje humani koagulacijski factor IX, ki je pridobljen in prečiščen iz človeške plazme (tekočega dela krvi).
Hypersensitivity (allergic reactions) has been sometimes seen in patients treated with factor IX-containing products.
Občasno so pri bolnikih, zdravljenih z zdravili, ki vsebujejo faktor IX, zabeležili preobčutljivostne (alergične) reakcije.
Why has Nonafact been approved?
Zakaj je bilo zdravilo Nonafact odobreno?
Haemophilia B patients may develop antibodies (inhibitors) to factor IX.
Pri bolnikih s hemofilijo B se lahko razvijejo protitelesa (zaviralci) faktorja IX.
How has Nonafact been studied?
Kako je bilo zdravilo Nonafact raziskano?
How does Nonafact work?
Kako zdravilo Nonafact deluje?
How is Nonafact used?
Kako se zdravilo Nonafact uporablja?
Nonafact was rated as “good” or “excellent” in its ability to prevent bleeding in patients with haemophilia B.
Učinkovitost zdravila Nonafact za preprečevanje krvavitev pri bolnikih s hemofilijo B je bila ocenjena kot „dobra“ ali „odlična“.
What is Nonafact?
Kaj je zdravilo Nonafact?
What is Nonafact used for?
Za kaj se zdravilo Nonafact uporablja?
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 January 2014
Datum prve odobritve: 16. januar 2014
Furthermore, the appropriate dose has not been established.
Poleg tega ustrezni odmerek ni bil določen.
Preliminary SVR12 data are available for 210 subjects.
Predhodni podatki SVR12 so na voljo za 210 oseb.
It will not work on its own.
Zdravilo ne deluje samo po sebi.
Eight subjects (20%) received epoetin and/or a blood product.
Osem oseb (20 %) je prejelo epoetin in/ali krvi pripravek.
Do not give this medicine to children and adolescents under 18 years of age.
Otroci in mladostniki Tega zdravila ne dajajte otrokom in mladostnikom, mlajšim od 18 let.
In 5 subjects (12.5%), study drugs were discontinued, modified or interrupted due to adverse events.
5 osebah (12,5 %) so uporabo študijskega zdravila zaradi neželenih učinkov ukinili, prilagodili ali prekinili.
The response rates observed for subjects over 65 years of age were similar to that of younger subjects across treatment groups.
Stopnje odziva, ki so jih opazili pri osebah, starejših od 65 let, so bile podobne kot pri mlajših osebah v vseh skupinah zdravljenja.
• If you are allergic to sofosbuvir or any of the other ingredients of this medicine (listed in section 6 of this leaflet).
• če ste alergični na sofosbuvir ali katero koli sestavino tega zdravila (navedeno v poglavju 6 tega navodila).
* Includes patients co-infected with human immunodeficiency virus (HIV).
* Vključno z bolniki, ki imajo sočasno okužbo z virusom človeške imunske pomanjkljivosti (HIV).
Response rates for selected subgroups are presented in Table 6.
Stopnje odzivov za izbrane podskupine so prisotne v preglednici 6.
This includes herbal medicines and medicines obtained without a prescription.
To vključuje tudi zeliščne pripravke in zdravila, ki ste jih dobili brez recepta.
Non-Black
Črnci Ne-črnci
Most subjects had no prior HCV treatment (81.3%).
Največ oseb se predhodno še niso zdravili zaradi HCV (81,3 %).
The proportions of subjects who were interferon intolerant, ineligible, or unwilling were 9%, 44%, and 47%, respectively.
Razmerje med osebami, ki so interferona niso prenašale, niso bile primerne oz. volje, je bilo 9 %, 44 % in 47 %.
Placebo recipients are not included in the tables since none achieved SVR12.
V preglednice niso vključene osebe, ki so dobivale placebo, saj nobena ni dosegla SVR12.
Clinical studies of sofosbuvir included 65 subjects aged 65 and over.
Klinične študije za sofosbuvir so vključevale 65 oseb, starih 65 let in več.
Interferon intolerant, ineligible or unwilling (POSITRON)
Interferona ne prenašajo, niso primerni ali niso voljni (POSITRON)
Patients awaiting liver transplantation - Study 2025
Bolniki, ki čakajo na presaditev jeter - študija 2025
Liver transplant recipients - Study 0126
Prejemniki presajenih jeter - študija 0126
Treatment-experienced (LONESTAR-2b)
Predhodno zdravljeni (LONESTAR-2b)
• severe headaches (migraine), memory loss, loss of concentration
• hudi glavoboli (migrena), izguba spomina, izguba koncentracije
Subjects in these studies had compensated liver disease including cirrhosis.
Osebe v teh študijah so imele kompenzirano bolezen jeter, vključno s cirozo.
Pharmacotherapeutic group: Direct-acting antiviral; ATC code: J05AX15
Farmakoterapevtska skupina: zdravilo z direktnim delovanjem na viruse; oznaka ATC: J05AX15
Virologic response in evaluable subjectsa a. Evaluable subjects are defined as those who have reached the specified time point at the time of the interim analysis.
Virološki odziv pri osebah, primernih za oceniteva a. Osebe, primerne za ocenitev, so opredeljene kot osebe, ki so v času vmesne analize dosegle specificirano časovno točko.
All subjects who achieved SVR12 achieved SVR24 and SVR48.
Vse osebe, ki so dosegle SVR12, so dosegle SVR24 in SVR48.
ANALEPTICS Modafinil
ANALEPTIKI Modafinil
Sovaldi is not recommended for use in children and adolescents under 18 years of age because the safety and efficacy have not been established in this population.
Uporaba zdravila Sovaldi se ne priporoča pri otrocih in mladostnikih, starih manj kot 18 let, saj varnost in učinkovitost pri tej populaciji nista bili dokazani.
The presence of 40% human serum had no effect on the anti-HCV activity of sofosbuvir.
Prisotnost 40 % humanega seruma ni vplivala na aktivnost sofosbuvirja proti HCV. Odpornost
Talk to your doctor or pharmacist if you have severe kidney problems or if you are on kidney dialysis as the effects of Sovaldi on patients with severe kidney problems have not been fully tested.
Posvetujte se z zdravnikom ali farmacevtom, če imate hude težave z ledvicami ali če ste na ledvični dializi, saj učinkov zdravila Sovaldi na bolnike s hudimi težavami z ledvicami niso v celoti preučili.
The film-coated tablet is for oral use.
Filmsko obložena tableta je za peroralno uporabo.
Frequencies are defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
Neželeni učinki so po pogostnosti opredeljeni kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) ali zelo redki (< 1/10.000).
SVR12 rate % (n/N)
Podskupina Stopnja SVR12 % (n/N)
↔ GS-331007 (TPV or BOC)
↔ GS-331007 (TPV ali BOC)
• Rifampicin and rifabutin (antibiotics used to treat infections, including tuberculosis);
• rifampicin in rifabutin (antibiotika, ki se uporablja za zdravljenje okužb, vključno s tuberkulozo);
If you accidentally take more than the recommended dose you should contact your doctor or nearest emergency department immediately for advice.
Če ste pomotoma vzeli večji odmerek od priporočenega, se takoj posvetujte z zdravnikom ali pojdite na najbližji oddelek nujne pomoči.
Blood tests may also show:
• zasoplost, kašelj Krvne preiskave lahko pokažejo tudi:
Subjects with genotype 2 or 3 HCV were enrolled in an approximately 1:3 ratio.
Osebe s HCV genotipa 2 ali 3 so bile vključene v razmerju približno 1:3.